<DOC>
	<DOCNO>NCT02331680</DOCNO>
	<brief_summary>This study investigate efficacy safety OPC-41061 24-week oral administration OPC-41061 15-mg 30-mg placebo patient chronic renal failure undergo hemodialysis hemodiafiltration daily urine volume least 500 mL/day .</brief_summary>
	<brief_title>A Trial Investigate Efficacy Safety Orally Administered Tolvaptan ( OPC-41061 ) Patients With Chronic Renal Failure Undergoing Hemodialysis Hemodiafiltration</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Chronic renal failure require hemodialysis hemodiafiltration 3 time week Daily urine volume â‰¥ 500 mL/day Male female patient age 20 80 year , inclusive Use one specify contraceptive method 4 week final IMP administration Capable provide write informed consent prior trialrelated procedure perform Patients complication urinary impairment due urinary tract stricture , urinary calculus , tumor urinary tract , cause Patients NYHA class IV heart failure Patients impaired hepatic function ( chronic hepatitis , druginduced liver injury ) Patients serious ischemic heart disease judge investigator subinvestigator inappropriate inclusion trial Patients serious arrhythmia judge investigator subinvestigator inappropriate inclusion trial Patients serious secondary hyperparathyroidism ( intact parathyroid hormone &gt; 500 pg/mL ) Patients concomitantly undergoing peritoneal dialysis Patients history cerebrovascular disease coronary artery disease within 4 week prior inform consent , history hypersensitivity ingredient tolvaptan benzazepine derivative mozavaptan hydrochloride history impair hepatic function ( chronic hepatitis , druginduced liver injury ) Patients follow abnormal laboratory value : hemoglobin &lt; 8.0 g/dL , total bilirubin &gt; 3.0 mg/dL , ALT ( GPT ) AST ( GOT ) &gt; 2 time upper limit reference range , serum sodium &gt; upper limit reference range , serum sodium &lt; 125 mEq/L , serum potassium &gt; 6.0 mEq/L Patients unable sense thirst difficulty fluid intake Patients receive OPC41061 history . Participation clinical trial postmarketing clinical study within 4 week prior inform consent present trial Female patient pregnant , possibly pregnant , nursing Patients otherwise judge investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Undergoing Hemodialysis</keyword>
	<keyword>Undergoing Hemodiafiltration</keyword>
</DOC>